SHINE Technologies has raised $240 million in equity funding, the company announced recently. The round was led by NantWorks with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of…
SHINE Technologies announced recently that it acquired Lantheus’ SPECT business, which includes the SPECT manufacturing facility in Massachusetts and its portfolio of diagnostic radiopharmaceuticals. “The nuclear medicine supply chain needs…
SHINE Technologies has entered into a strategic partnership with Standard Nuclear, a reactor-agnostic producer of TRISO nuclear fuel and radioisotope power systems, SHINE announced today. According to a release, the…
SHINE Technologies has entered into a definitive agreement to acquire the SPECT business from Lantheus, a radiopharmaceutical-focused company, the company announced recently. Lantheus’ SPECT product portfolio includes imaging agents for…
SHINE Technologies and Modawina Medical Company (MMC) have entered a strategic distribution partnership to bring Ilumira, SHINE’s non-carrier-added lutetium-177, to patients in the United Arab Emirates, the company announced recently….
SHINE Technologies is partnering with Sumitomo Corporation of Americas (SCOA), a leading global trading and investment company, the company announced today. According to a release, the partnership, formalized through a…
SHINE Technologies has been selected to provide a 14 mega electron volt deuterium-tritium fusion system to the U.K. Atomic Energy Authority (UKAEA)’s Lithium Breeding Tritium Innovation (LIBRTI) program in 2027,…
SHINE Technologies has partnered with Antelope Surgical Solutions, a biotech company pioneering next-generation multimodal radiopharmaceuticals, the company announced recently. According to a release, the supply agreement will accelerate Antelope’s clinical…
SHINE Technologies is partnering with Primo Biotechnology, a developer of high-precision radiopharmaceuticals, the company announced today. According to a release, the agreement grants Primo exclusive distribution rights for SHINE’s Ilumira…
SHINE Technologies and WARF Therapeutics today announced pre-clinical research results from collaborative efforts with the Advanced Radiotheranostics Lab at the University of Wisconsin. According to a release, the studies showed…
